Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
Cape Heart Institute, University of Cape Town, Cape Town, South Africa.
Front Immunol. 2022 Sep 6;13:992022. doi: 10.3389/fimmu.2022.992022. eCollection 2022.
Multisystem inflammatory syndrome in children (MIS-C) is a severe acute inflammatory reaction to SARS-CoV-2 infection in children. There is a lack of data describing differential expression of immune genes in MIS-C compared to healthy children or those with other inflammatory conditions and how expression changes over time. In this study, we investigated expression of immune-related genes in South African MIS-C patients and controls.
The cohort included 30 pre-treatment MIS-C cases and 54 healthy non-inflammatory paediatric controls. Other controls included 34 patients with juvenile systemic lupus erythematosus, Kawasaki disease or other inflammatory conditions. Longitudinal post-treatment MIS-C specimens were available at various timepoints. Expression of 80 immune-related genes was determined by real-time quantitative PCR.
A total of 29 differentially expressed genes were identified in pre-treatment MIS-C compared to healthy controls. Up-regulated genes were found to be overrepresented in innate immune pathways including interleukin-1 processing and pyroptosis. Post-treatment follow-up data were available for up to 1,200 hours after first treatment. All down-regulated genes and 17/18 up-regulated genes resolved to normal levels in the timeframe, and all patients clinically recovered. When comparing MIS-C to other febrile conditions, only expression could differentiate these two groups with high sensitivity and specificity.
These data indicate a unique 29-gene signature of MIS-C in South African children. The up-regulation of interleukin-1 and pyroptosis pathway genes highlights the role of the innate immune system in MIS-C. IL-27 is a potent anti-inflammatory and antiviral cytokine that may distinguish MIS-C from other conditions in our setting.
儿童多系统炎症综合征(MIS-C)是儿童感染 SARS-CoV-2 后的一种严重急性炎症反应。目前缺乏数据描述 MIS-C 与健康儿童或其他炎症性疾病儿童相比免疫基因的差异表达,以及这些表达如何随时间变化。在这项研究中,我们调查了南非 MIS-C 患者和对照者的免疫相关基因表达。
该队列包括 30 例治疗前 MIS-C 病例和 54 例健康非炎症性儿科对照者。其他对照者包括 34 例青少年系统性红斑狼疮、川崎病或其他炎症性疾病患者。在不同时间点获得了纵向治疗后 MIS-C 标本。通过实时定量 PCR 测定 80 个免疫相关基因的表达。
与健康对照者相比,治疗前 MIS-C 共鉴定出 29 个差异表达基因。上调基因在先天免疫途径中过表达,包括白细胞介素-1 加工和细胞焦亡。在首次治疗后最多可获得 1200 小时的治疗后随访数据。所有下调基因和 17/18 个上调基因在该时间范围内恢复正常水平,所有患者临床康复。当将 MIS-C 与其他发热性疾病进行比较时,只有 表达可以用高灵敏度和特异性来区分这两组。
这些数据表明南非儿童 MIS-C 存在独特的 29 基因特征。白细胞介素-1 和细胞焦亡途径基因的上调突出了先天免疫系统在 MIS-C 中的作用。IL-27 是一种有效的抗炎和抗病毒细胞因子,可能在我们的环境中区分 MIS-C 与其他疾病。